JAZZ Jazz Pharmaceuticals plc

+3.44  (+3%)
Previous Close 131.39
Open 131.84
Price To Book 2.56
Market Cap 7,634,228,171
Shares 56,621,139
Volume 246,118
Short Ratio
Av. Daily Volume 456,814

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 26, 2019 met primary endpoint.
PF743 (JZP-458)
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
Phase 2 enrollment initiation announced February 8, 2017.
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
Excessive sleepiness associated with obstructive sleep apnea
FDA Approval announced March 20, 2019.
Excessive sleepiness associated with narcolepsy
Phase 3 timing of interim analysis due 2019.
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Acute myeloid leukemia
Phase 2 enrolment to be completed 2019.
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
Idiopathic Hypersomnia
Phase 1/2 presentation at ASCO May 31, 2019.
Acute myeloid leukemia (AML)
Phase 1b data due 2H 2019.
Vyxeos in combination with venetoclax
First-line unfit Acute myeloid leukemia
Phase 2/3 trial to be initiated later in 2019.
Acute lymphoblastic leukemia (ALL)

Latest News

  1. Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?
  2. Jazz buys Virginia biotech firm in deal valued at up to $312.5M
  3. Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
  4. The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
  5. Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
  6. (PFNX) Q2 2019 Earnings Call Transcript
  7. Edited Transcript of JAZZ earnings conference call or presentation 6-Aug-19 8:30pm GMT
  8. Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
  9. Jazz Pharmaceuticals Sings a Sweet Tune in Q2
  10. Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
  11. Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results
  12. Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
  13. What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
  14. Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
  15. Is There An Opportunity With Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) 34% Undervaluation?
  16. Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
  17. Jazz (Pharmaceuticals) Has Pizzazz With Quant Upgrade and Bullish Charts
  18. Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
  19. Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
  20. 3 Incredibly Cheap Healthcare Stocks